
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers, with a strong focus on their product, the Melphalan/HDS system. With a strong pipeline of new treatments and a growing network of active centers, the company is well-positioned for continued growth in the oncology market. Furthermore, Delcath's recent partnership with the National Cancer Institute and focus on strengthening its referral network indicates strong potential for future success.
Bears say
Delcath Systems is seeing growth in its product sales but at a slower rate than expected due to pricing pressures. With 340B pricing cutting effective ASP and limited volume growth, the company is facing challenges in increasing its revenue and profitability. However, the company's pipeline shows potential for future growth with ongoing trials for liver-dominant metastatic colorectal and breast cancer, but it may take time for results to materialize.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares